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Background: Diabetic patients may have a higher risk of gastric cancer. However, whether they have a higher
incidence of Helicobacter pylori (HP) eradication is not known. Furthermore, whether insulin use in patients with
type 2 diabetes may be associated with a higher incidence of HP eradication has not been investigated.
Methods: This is a retrospective cohort study. The reimbursement databases from 1996 to 2005 of 1 million insurants of
the National Health Insurance in Taiwan were retrieved. After excluding those aged <25 years, cases of gastric cancer,
cases receiving HP eradication before 2005, patients with type 1 diabetes mellitus and those with unknown living region,
the reimbursement data of a total of 601,441 insurants were analyzed. Diabetes status and insulin use in patients with type
2 diabetes before 2005 were the main exposures of interest and the first event of HP eradication in 2005 was the main
outcome evaluated. HP eradication was defined as a combination use of proton pump inhibitor or H2 receptor blockers,
plus clarithromycin or metronidazole, plus amoxicillin or tetracycline, with or without bismuth, in the same prescription for
7-14 days. The association between type 2 diabetes/insulin use and HP eradication was evaluated by logistic regression,
considering the confounding effect of diabetes duration, comorbidities, medications and panendoscopic examination.
Results: In 2005, there were 10,051 incident cases receiving HP eradication. HP eradication was significantly increased with
age, male sex, diabetes status, insulin use, use of calcium channel blocker, panendoscopic examination, hypertension,
dyslipidemia, chronic obstructive pulmonary disease, stroke, nephropathy, ischemic heart disease and peripheral arterial
disease. Significant differences were also seen for occupation and living region. Medications including statin, fibrate,
angiotensin-converting enzyme inhibitor/angiotensin receptor blocker and oral anti-diabetic agents were not associated
with HP eradication. The adjusted odds ratios for diabetes, insulin use and use of calcium channel blocker was 1.133
(1.074, 1.195), 1.414 (1.228, 1.629) and 1.147 (1.074, 1.225), respectively.
Conclusions: Type 2 diabetes and insulin use in the diabetic patients are significantly associated with a higher incidence
of HP eradication. Additionally, use of calcium channel blocker also shows a significant association with HP eradication.
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Our population-based cohort study showed that patients
with type 2 diabetes mellitus (T2DM) have a significantly
higher risk of gastric cancer mortality [1]. Helicobacter pyl-
ori (HP) infection is the most important etiology for gastric
cancer, and its eradication can significantly reduce gastric
cancer in carriers without precancerous lesions [2].
However, the link between diabetes and HP infection
has been inconsistently reported. Case-control studiesCorrespondence: ccktsh@ms6.hinet.net
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any medium, provided the original work is propsuggested that patients with type 1 diabetes mellitus
(T1DM) do not have a higher prevalence of HP infection
[3,4] and the prevalence may decrease with longer dur-
ation of diabetes [3]. Successful HP eradication rates in
patients with T1DM and T2DM are 62% and 50%, re-
spectively, which are much lower than the recommended
80% [5-7]. Furthermore, reinfection rate is higher in
patients with T1DM [8,9], and it may deteriorate meta-
bolic control, leading to the requirement of higher insu-
lin dosage and development of diabetic complications
[8,9].
Studies regarding HP infection rate in patients with
T2DM are still scarce. A hospital-based case-control study
from Pakistan enrolling 74 patients with T2DM and 74is is an Open Access article distributed under the terms of the Creative Commons
/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
erly cited.
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a higher infection rate (73% vs. 51.4%) [10]. Similarly, a
higher infection rate is observed in 210 patients with
T2DM (vs. 210 controls) in a study from the United Arab
Emirates [11]. On the other hand, a Turkish study in 141
patients with T2DM and 142 controls showed no
significant difference between the two groups [12].
Based on the above observations, it is reasonable to
hypothesize that diabetic patients might have a higher HP
infection rate or a higher clinical activity of the infection
requiring eradication therapy. It is also possible that
patients with T2DM and with poor glycemic control, who
require insulin therapy, may represent a group of high risk
patients for HP eradication. Population-based study and
incidence data evaluating these hypotheses have not been
reported. Therefore, by using the population-based reim-
bursement databases of the National Health Insurance
(NHI) in Taiwan, the present study tests these hypotheses
by evaluating the incidence and odds ratios of HP eradica-
tion in patients with T2DM versus non-diabetic subjects;
and in insulin users versus non-users among the patients
with T2DM. The effects of diabetes duration, comorbid-
ities, medications and the frequency of panendoscopic
examination (PES) were also considered in the analyses.
Methods
Study population
This is a retrospective cohort study using the reimburse-
ment databases of the NHI of Taiwan. According to the
Ministry of Interior, >98.0% of the Taiwanese population
in 2005 (22,770,383: 11,562,440 men and 11,207,943
women) were covered by the NHI [13]. A random sam-
ple of 1,000,000 insurants in 2005 was created by the
National Health Research Institute. The National HealthA random sample of 1,000,000 subjects from the National He
and the subjects’ reimbursement databases were
Excluding: 
<25 years old, type 1 diab
with a diagnosis of gastric
Helicobacter pylori eradic
Excluding: diabetes diagno
Calculation of annual incidence in 2005 
(Incident case number=10,051) 
Subjects ≥ 25 years old and without type 1 diabetes   
(n=601,441)
Figure 1 Flowchart showing the procedures in the calculation of the
Taiwan using the National Health Insurance database.Research Institute is the only institute approved, as per
local regulations, for conducting sampling of a represen-
tative sample of the whole population for the year 2005
with a predetermined sample size of 1,000,000 indivi-
duals. The reimbursement databases of these individuals
were retrieved and could be provided for academic re-
search after approval. The identification information was
scrambled for the protection of the privacy of the
individuals.
Figure 1 shows a flowchart for selecting cases for the
study. After excluding subjects <25 years old, patients
with T1DM (in Taiwan, patients with T1DM were issued
a “Severe Morbidity Card” after certified diagnosis), liv-
ing region unknown, cases with a diagnosis of gastric
cancer and cases receiving HP eradication before 2005,
the data of 601,441 subjects were analyzed.
Data retrieved from NHI databases
The reimbursement databases were available back to 1996.
Identification number, sex, birth date, medications and
diagnostic codes based on the International Classification
of Diseases, Ninth Revision, Clinical Modification (ICD-9-
CM) were retrieved. Diabetes was coded 250.1-250.9 and
gastric cancer 151. The comorbidities (ICD-9-CM codes)
included hypertension (401-405), chronic obstructive pul-
monary disease (490-496, a surrogate for smoking), stroke
(430-438), nephropathy (580-589), ischemic heart disease
(410-414), peripheral arterial disease (250.7, 785.4, 443.81,
440-448), eye disease (250.5, 362.0, 369, 366.41, 365.44),
obesity (278) and dyslipidemia (272.0-272.4).
Medications included statin, fibrate, angiotensin-
converting enzyme inhibitor and/or angiotensin receptor
blocker, calcium channel blocker, sulfonylurea, metformin,
insulin, acarbose, pioglitazone and rosiglitazone. The NHIalth Insurance in 2005 was created  
 retrieved back to1996
etes, living region unknown, cases 
 cancer and cases receiving 
ation before 2005 
sed <5 years 
Subjects ≥ 25 years old, without type 1 diabetes and without
type 2 diabetes diagnosed <5 years  
(n=572,790) 
Calculation of annual incidence in 2005 
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annual incidence of Helicobacter pylori eradication in 2005 in
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served as a surrogate for socioeconomic status. The living
region served as a surrogate for geographical distribution
of some environmental exposure. Occupation was
categorized as I: civil servants, teachers, employees of
governmental or private business, professionals and tech-
nicians; II: people without particular employers, self-
employed or seamen, III: farmers or fishermen; and IV:
low-income families supported by social welfare or veter-
ans. Living region was categorized as Taipei, Northern,
Central, Southern and Kao-Ping/Eastern.
The methods for identifying patients receiving HP
eradication therapy in a previous study were followed
[14]. The details for all therapeutic regimens are shown
in the supplementary Table 1 of this earlier paper. In
brief, HP eradication therapy was defined as a
combination use of proton pump inhibitor or H2 recep-
tor blockers, plus clarithromycin or metronidazole, plus
amoxicillin or tetracycline, with or without bismuth, in
the same prescription order for 7-14 days.
Statistical analyses
Diabetes status and insulin use were considered as the
exposures of interest and HP eradication as the outcome in
the study. To assure the correctness of temporal order of
exposure and outcome, age, diabetes status, diabetes dur-
ation, use of insulin or other medications, and comorbidities
were recorded as a status or diagnosis before January 1,
2005; and HP eradication was recorded as a first event
occurring in the year 2005. PES done in 2005 and from
1997 to 2005 were both analyzed. The purpose to include
PES done in 2005 was to assure the temporal proximity of
performing PES which might be related to the conduction
of HP eradication.
The baseline characteristics between diabetic and non-
diabetic subjects were compared by Student’s t test for
continuous variables and by Chi square test for categor-
ical variables.
Chi square test examined the differences of annual in-
cidence of HP eradication among subgroups of age (25-
44, 45-54, 55-64 and ≥65 years), sex, diabetes (for all
subjects), insulin use (for diabetic patients only), occupa-
tion and living region, for all subjects and for the dia-
betic patients only separately, before and after excluding
patients with diabetes diagnosed <5 years (Figure 1).
Logistic regression estimated the mutually-adjusted
odds ratios for HP eradication in all subjects and in the
diabetic patients only. For the diabetic patients only, the
independent variables included age, sex, PES (1997-
2005), the above-mentioned comorbidities, living region,
occupation and all the above-mentioned medications.
For all subjects, the independent variables included age,
sex, diabetes, PES (1997-2005), the above-mentioned
comorbidities, medications other than anti-diabetictherapies (i.e., statin, fibrate, angiotensin-converting en-
zyme inhibitor and/or angiotensin receptor blocker, cal-
cium channel blocker), living region and occupation.
Additional logistic models were created to examine
whether the magnitude of the odds ratios for diabetes status
(for all subjects), diabetes duration (for all subjects) and in-
sulin use (for the diabetic patients only) might change by in-
cluding different sets of covariates. Model I was adjusted for
age and sex; model II for age, sex, occupation and living re-
gion; model III for age, sex, occupation, living region, PES
(in 2005), hypertension, chronic obstructive pulmonary
disease, stroke, nephropathy, ischemic heart disease, periph-
eral arterial disease, eye disease, obesity and dyslipidemia;
model IV for age, sex, occupation, living region, PES (in
2005), hypertension, chronic obstructive pulmonary disease,
stroke, nephropathy, ischemic heart disease, peripheral ar-
terial disease, eye disease, obesity, dyslipidemia, statin,
fibrate, angiotensin converting enzyme inhibitor/angioten-
sin receptor blocker and calcium channel blocker (model
IV in diabetic patients only was additionally adjusted for
oral anti-diabetic agents including sulfonylurea, metformin,
acarbose, pioglitazone and rosiglitazone).
Analyses were conducted using SAS statistical soft-
ware, version 9.1 (SAS Institute, Cary, NC). Data were
expressed as mean (standard deviation) for continuous
variables or number (%) for categorical variables.
P< 0.05 was considered statistically significant.
Results
Table 1 compares the baseline characteristics between
diabetic and non-diabetic subjects. The diabetic
patients were older and female predominant, and had
higher prevalence rates of comorbidities, medication
use and PES (in 2005 or 1997-2005).
The annual incidences of HP eradication in different
groups are shown in Table 2. HP eradication rates
increased with increasing age, and were higher in
men, diabetic patients and insulin users. Significant
differences were also seen for occupation and living
region.
The mutually-adjusted odds ratios for HP eradication
are shown in Table 3. For all subjects, age, male sex, dia-
betes, PES (1997-2005), hypertension, chronic obstruct-
ive pulmonary disease, stroke, nephropathy, ischemic
heart disease, peripheral arterial disease, dyslipidemia,
calcium channel blocker, living region (northern and
central) and occupation (III and IV) were significantly
associated with a higher incidence. Except for dyslipide-
mia and living region in northern Taiwan, the significant
variables for the diabetic patients only were all the same
as in the model for all subjects. Furthermore, insulin use
was significantly associated with HP eradication.
The unadjusted and adjusted odds ratios for HP
eradication for diabetes status (for all subjects), diabetes
Table 1 Baseline characteristics of study subjects aged 25 years or older by diabetes status
Variable Diabetes mellitus
No Yes P value
n or mean % or SD n or mean % or SD
n (%) 511519 85.05 89922 14.95
Age (years) 43.98 14.00 58.01 14.95 <0.0001
Sex (men, %) 253626 49.58 39950 44.43 <0.0001
Hypertension (%) 79292 15.50 50549 56.21 <0.0001
Chronic obstructive pulmonary disease (%) 105693 20.66 36273 40.34 <0.0001
Stroke (%) 24744 4.84 18484 20.56 <0.0001
Nephropathy (%) 24780 4.84 15971 17.76 <0.0001
Ischemic heart disease (%) 40465 7.91 28523 31.72 <0.0001
Peripheral arterial disease (%) 15732 3.08 12683 14.10 <0.0001
Eye disease (%) 1170 0.23 8763 9.75 <0.0001
Obesity (%) 4180 0.82 2410 2.68 <0.0001
Dyslipidemia (%) 51126 9.99 44973 50.01 <0.0001
Statin (%) 19608 3.83 24481 27.22 <0.0001
Fibrate (%) 16084 3.14 19053 21.19 <0.0001
Angiotensin-converting enzyme inhibitor/
Angiotensin receptor blocker (%)
6904 1.35 6638 7.38 <0.0001
Calcium channel blocker (%) 34889 6.82 18908 21.03 <0.0001
Occupation (%)
I 282985 55.32 35103 39.04 <0.0001
II 82588 16.15 17037 18.95
III 61580 12.04 19708 21.92
IV 84366 16.49 18074 20.10
Living region (%)
Taipei 193494 37.83 31534 35.07 <0.0001
Northern 74045 14.48 11182 12.44
Central 91087 17.81 15664 17.42
Southern 66785 13.06 14807 16.47
Kao-Ping/Eastern 86108 16.83 16735 18.61
Panendoscopic examination in 2005 8211 1.61 2834 3.15 <0.0001
Panendoscopic examination in 1997-2005 37759 7.38 11762 13.08 <0.0001
Diabetic patients only
Sulfonylurea (%) - - 37211 41.38
Metformin (%) - - 33106 36.82
Insulin (%) - - 6010 6.68
Acarbose (%) - - 6968 7.75
Pioglitazone (%) - - 2329 2.59
Rosiglitazone (%) - - 6538 7.27
Data are expressed as n (%) or mean (SD). *Occupation categories are explained in “Materials and Methods”.
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patients only) are shown in Table 4. Diabetes was asso-
ciated with a significantly higher odds ratio of HP eradi-
cation in all models, though the odds ratio attenuated
when more covariates were adjusted, especially when the
comorbidities were considered (models III and IV). The
odds ratios attenuated with increasing diabetes durationand with adjustment for covariates, especially when
comorbidities and medications were included. The odds
ratios became insignificant for diabetes duration of more
than 3 years in models III and IV. Insulin use was signifi-
cantly associated with a higher odds ratio though the
magnitude of the odds ratios attenuated slightly after ad-
justment for covariates.
Table 2 Annual incidence (per 100,000) of Helicobacter pylori eradication in 2005 in Taiwan
Variable Excluding diabetes diagnosed <5 years
No Yes
n Incidence P n Incidence P
All subjects
Age (years)
25-44 3250 1009.44 <0.0001 3066 974.82 <0.0001
45-54 2370 1805.69 2134 1725.63
55-64 1687 2469.52 1462 2352.68
≥65 2744 3433.69 2378 3281.67
Sex
Men 5142 1751.51 <0.0001 4612 1648.96 <0.0001
Women 4909 1594.53 4428 1510.76
Diabetes
No 7129 1393.69 <0.0001 7129 1393.69 <0.0001
Yes 2922 3249.48 1911 3118.93
Occupation*
I 4272 1343.02 <0.0001 3915 1277.81 <0.0001
II 1815 1821.83 1640 1744.48
III 2023 2488.68 1764 2332.50
IV 1941 1894.77 1721 1778.46
Living region
Taipei 3471 1542.47 <0.0001 3123 1455.34 <0.0001
Northern 1220 1431.47 1103 1349.10
Central 1670 1564.39 1486 1461.00
Southern 1623 1989.17 1449 1874.95
Kao-Ping/Eastern 2067 2009.86 1879 1928.17
Diabetic patients only
Age (years)
25-44 374 1999.57 <0.0001 190 1687.09 <0.0001
45-54 568 2789.51 332 2598.83
55-64 677 3435.33 452 3339.24
≥65 1303 4183.12 937 3953.92
Sex
Men 1380 3454.32 0.0020 850 3260.95 0.0818
Women 1542 3085.73 1061 3013.78
Insulin use
No 2619 3121.13 <0.0001 1678 2979.72 <0.0001
Yes 303 5041.60 233 4700.42
Occupation*
I 963 2743.36 <0.0001 606 2589.96 <0.0001
II 521 3058.05 346 3028.98
III 778 3947.64 519 3694.74
IV 660 3651.65 440 3547.53
Living region
Taipei 962 3050.68 0.0002 614 2910.64 <0.0001
Northern 330 2951.17 213 2761.57
Tseng BMC Gastroenterology 2012, 12:46 Page 5 of 9
http://www.biomedcentral.com/1471-230X/12/46
Table 2 Annual incidence (per 100,000) of Helicobacter pylori eradication in 2005 in Taiwan (Continued)
Central 489 3121.81 305 2870.86
Southern 548 3700.95 374 3562.92
Kao-Ping/Eastern 593 3543.47 405 3570.80
n= case number of Helicobacter pylori eradication.
*Occupation categories are explained in “Materials and Methods”.
Chi-square test was used for the statistical analysis.
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This study provided for the first time a nation-wide popu-
lation-based analysis with a large sample size on the asso-
ciation between T2DM and HP eradication. Diabetes was
significantly associated with a higher incidence of HP
eradication (Tables 2, 3, 4), independent of comorbidities,Table 3 Mutually-adjusted odds ratios for Helicobacter pylori
Study/Variable Interpretation
Age Every 1-year increment
Sex Men vs. Women
Diabetes Yes vs. No
Panendoscope examination (1997-2005) Yes vs. No
Hypertension Yes vs. No
Chronic obstructive pulmonary disease Yes vs. No
Stroke Yes vs. No
Nephropathy Yes vs. No
Ischemic heart disease Yes vs. No
Peripheral arterial disease Yes vs. No
Eye disease Yes vs. No
Obesity Yes vs. No
Dyslipidemia Yes vs. No
Statin Yes vs. No




Calcium channel blocker Yes vs. No




Occupation II vs. I
III vs. I
IV vs. I
Sulfonylurea Yes vs. No
Metformin Yes vs. No
Insulin Yes vs. No
Acarbose Yes vs. No
Pioglitazone Yes vs. No
Rosiglitazone Yes vs. No
*Occupation categories are explained in “Materials and Methods”.medications, PES, occupation and living region (Tables 3
and 4). The odds ratios attenuated with increasing dia-
betes duration, probably due to the increased occurrence
of comorbidities, which might also affect the incidence of
HP eradication (Table 4). Furthermore, use of calcium
channel blockers (Table 3) and insulin use in the diabeticeradication in 2005 in Taiwan
Adjusted odds ratio (95% confidence interval)
All subjects Diabetic patients only
1.014 (1.012, 1.015) 1.008 (1.005, 1.011)
1.220 (1.171, 1.270) 1.155 (1.071, 1.247)
1.133 (1.074, 1.195) –
8.940 (8.573, 9.321) 5.592 (5.173, 6.045)
1.199 (1.129, 1.273) 1.215 (1.098, 1.345)
1.257 (1.202, 1.314) 1.214 (1.121, 1.313)
1.119 (1.051, 1.191) 1.096 (1.000, 1.201)
1.268 (1.193, 1.347) 1.314 (1.203, 1.435)
1.246 (1.179, 1.317) 1.183 (1.086, 1.289)
1.126 (1.048, 1.211) 1.133 (1.025, 1.252)
0.937 (0.833, 1.053) 0.898 (0.784, 1.029)
0.971 (0.816, 1.155) 0.815 (0.627, 1.061)
1.174 (1.110, 1.242) 1.034 (0.948, 1.127)
1.013 (0.946, 1.086) 1.015 (0.923, 1.116)
1.015 (0.944, 1.091) 1.007 (0.913, 1.110)
1.011 (0.912, 1.121) 1.051 (0.913, 1.211)
1.147 (1.074, 1.225) 1.108 (1.004, 1.224)
1.103 (1.042, 1.168) 1.082 (0.968, 1.208)
1.124 (1.056, 1.195) 1.140 (1.022, 1.271)
1.027 (0.969, 1.088) 1.047 (0.941, 1.165)
ei 0.988 (0.924, 1.058) 0.979 (0.859, 1.116)
1.022 (0.961, 1.087) 1.023 (0.910, 1.148)
1.317 (1.235, 1.404) 1.286 (1.144, 1.445)
1.308 (1.235, 1.386) 1.205 (1.080, 1.345)
- 0.978 (0.875, 1.093)
- 0.972 (0.867, 1.091)
- 1.414 (1.228, 1.629)
- 1.004 (0.863, 1.167)
- 0.999 (0.787, 1.269)
- 0.939 (0.800, 1.101)
Table 4 Odds ratios for Helicobacter pylori eradication for diabetes status, diabetes duration and insulin use
Diabetes-related variable Odds ratio (95% confidence interval)
Unadjusted Adjusted
Model I Model II Model III Model IV
All subjects
Non-diabetes 1.000 1.000 1.000 1.000 1.000
Diabetes 2.376 (2.275, 2.482) 1.644 (1.569, 1.723) 1.633 (1.558, 1.711) 1.132 (1.062, 1.208) 1.137 (1.065, 1.213)
All subjects
Non-diabetes 1.000 1.000 1.000 1.000 1.000
Diabetes <1 year 3.596 (3.217, 4.020) 2.736 (2.444, 3.061) 2.721 (2.431, 3.045) 1.772 (1.522, 2.062) 1.772 (1.522, 2.062)
Diabetes 1-3 years 2.273 (2.062, 2.506) 1.695 (1.536, 1.871) 1.681 (1.523, 1.855) 1.293 (1.139 1.468) 1.289 (1.135, 1.463)
Diabetes 3-5 years 2.178 (1.977, 2.398) 1.587 (1.439, 1.750) 1.575 (1.428, 1.737) 1.057 (0.931, 1.200) 1.053 (0.927, 1.196)
Diabetes ≥5 years 2.303 (2.182, 2.430) 1.513 (1.428, 1.602) 1.503 (1.419, 1.592) 1.015 (0.938, 1.098) 1.022 (0.944, 1.106)
Diabetic patients only
Non-insulin users 1.000 1.000 1.000 1.000 1.000
Insulin users 1.648 (1.459, 1.862) 1.495 (1.322, 1.690) 1.483 (1.311, 1.677) 1.319 (1.127, 1.543) 1.389 (1.178, 1.639)*
I: Adjusted for age and sex.
II: Adjusted for age, sex, occupation and living region.
III: Adjusted for age, sex, occupation, living region, panendoscopic examination (in 2005), hypertension, chronic obstructive pulmonary disease, stroke,
nephropathy, ischemic heart disease, peripheral arterial disease, eye disease, obesity and dyslipidemia.
IV: Adjusted for age, sex, occupation, living region, panendoscopic examination (in 2005), hypertension, chronic obstructive pulmonary disease, stroke,
nephropathy, ischemic heart disease, peripheral arterial disease, eye disease, obesity, dyslipidemia, statin, fibrate, angiotensin converting enzyme inhibitor/
angiotensin receptor blocker and calcium channel blocker.
*Model IV in diabetic patients only was additionally adjusted for oral anti-diabetic agents including sulfonylurea, metformin, acarbose, pioglitazone and
rosiglitazone.
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with HP eradication.
The higher incidence of HP eradication associated with
diabetes could be explained by the following possibilities:
the diabetic patients might have a higher chance of being
detected for HP infection, or they might have a higher HP
infection rate or a higher activity of HP infection. A
higher detection rate is possible because the diabetic
patients were more prone to have PES (Table 1). However,
this could not explain the whole picture because the
higher incidence of HP eradication associated with dia-
betes remained significant after adjustment for PES and
other covariates (Tables 3 and 4). Currently we do not
have HP infection rates in Taiwanese diabetic and non-
diabetic subjects. Some studies suggested that the HP in-
fection rates are similar between non-diabetic and diabetic
subjects in patients with either T1DM [3,4] or T2DM
[12]. If this is the case, the higher incidence of HP eradi-
cation associated with diabetes (Tables 2, 3, 4) may impli-
cate that HP infection in the diabetic patients is more
clinically active with more severe symptoms, leading to its
diagnosis and the use of medications for its eradication.
Insulin use was consistently associated with a higher
incidence of HP eradication, but none of the oral anti-
diabetic agents was (Tables 2, 3, 4). Insulin use may be
a proxy for uncontrollable hyperglycemia with more
severe disease. Therefore this observation might be
explained in the following ways. HP infected patients
might have deteriorated metabolic control [8,9] andrequired insulin therapy; or they might have more se-
vere diabetic conditions (e.g., diabetic gastroparesis)
with gastrointestinal symptoms leading to more ag-
gressive examination and diagnosis of HP infection.
A significantly higher rate of HP eradication was
seen in subjects taking calcium channel blockers
(Table 3). It is interesting that calcium channel block-
ers are also associated with gastroesophageal reflux
disease, probably due to its relaxation effect on lower
esophageal sphincter [15]. HP infection can induce
pepsinogen release from chief cells (which may induce
and aggravate peptic ulcer disease) via mechanisms in-
volving calcium and calmodulin [16]. However, L-type
calcium channel is not responsible for the pepsinogen
release induced by HP [16]. Therefore it is unlikely
that calcium channel blockers used in clinical practice
would affect the peptic ulcers induced by HP. It was
possible that the gastrointestinal symptoms associated
with its use that led to the diagnosis of HP infection.
Recent studies suggest that HP eradication may re-
verse atrophic gastritis and improve intestinal metapla-
sia, which may contribute to the reduction of gastric
cancer occurrence [17-19]. Therefore, early diagnosis
of HP infection with clinical use of medications to
eradicate the infection is not only important for the
treatment of the clinical symptoms related to the in-
fection, but also for the prevention of gastric cancer.
One clinical implication of the present study is that
patients with T2DM, especially those treated with
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special medical attention.
HP infection rate in a community-based study in Taiwan
was 54.4%, and it showed age-dependency without sexual
difference [20]. Although the present study suggested that
clinical presentation of HP eradication was age-dependent
(Tables 2 and 3), it also demonstrated a higher incidence of
HP eradication in the male population (Tables 2 and 3).
The reasons for a higher risk of HP eradication in men are
still unknown. One possibility is that the activity of HP
infection could be higher in men, which is correspondent
to the higher risk of gastric cancer in men than in women
in Taiwan [1].
Except for eye disease, obesity and dyslipidemia (in
diabetic patients only) all other comorbidities were signifi-
cantly associated with HP eradication (Table 3). This obser-
vation explained the attenuated odds ratios with prolonged
diabetes duration (Table 4), when chronic complications
might set in and interfere with the association between dia-
betes and HP eradication.
Some studies suggested that people living in crowded
condition or with lower socioeconomic status may have a
higher risk of HP infection [21-23]. In Taiwan, Taipei City
is the most populated area. However, residents in
relatively sparse area of Central Taiwan had significantly
higher incidence of HP eradication than people living in
other regions (Table 3). This suggested that living in
crowded condition might not be an important predispos-
ing factor. On the other hand, people with an occupation
as farmers or fishermen (occupation III) or with low fam-
ily income (occupation IV) consistently showed signifi-
cantly higher odds ratios (Table 3), suggesting a possible
role of socioeconomic status or its related condition of
hygiene.
This study has several strengths. It is population-based
with a large nationally representative sample, therefore, the
study is not likely to be biased with respect to diabetes
status or records of HP eradication. Because NHI is a
universal and mandatory insurance with very high coverage
but low co-payments, the detection rate would not tend to
differ among different social classes.
Limitations included a lack of actual measurement of
some recognized confounders such as personal hygiene,
living condition, blood groups and genetic factors. We
also did not have biochemical data including blood glu-
cose, hemoglobin A1c and lipid profiles to evaluate
whether HP infection can affect metabolic control. This
study evaluated the incidence of HP eradication and not
the prevalence or incidence of HP infection. However,
because most people infected with HP do not develop
clinical disease [21], estimation of prevalence or inci-
dence of HP infection may not have clinical relevance as
the evaluation of HP eradication does. Another concern
is that there might be considerable under-diagnosis andunder-treatment of HP infection. However, if the mis-
classification of the outcome is non-differential, an
underestimation of the odds ratios is expected.
Conclusions
This study shows a significantly higher incidence of HP
eradication in patients with T2DM and in insulin users
among the diabetic patients. The odds ratios attenuated
with increasing diabetes duration, probably due to the
occurrence of other comorbidities. Additionally, lower
socioeconomic status and use of calcium channel block-
ers consistently show a higher rate of HP eradication,
but the uses of oral anti-diabetic agents do not. The
underlying causes for the link between T2DM and the
use of medications and HP eradication are clinically im-
portant but require further investigation.
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